Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Published on Mar 30, 2016in Cochrane Database of Systematic Reviews7.89
· DOI :10.1002/14651858.CD004179.PUB2
Rachel Forster8
Estimated H-index: 8
(Edin.: University of Edinburgh),
Marlene C. W. Stewart20
Estimated H-index: 20
(Edin.: University of Edinburgh)
Sources
Abstract
Background The optimal duration of thromboprophylaxis after total hip or knee replacement, or hip fracture repair remains controversial. It is common practice to administer prophylaxis using low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH) until discharge from hospital, usually seven to 14 days after surgery. International guidelines recommend extending thromboprophylaxis for up to 35 days following major orthopaedic surgery but the recommendation is weak due to moderate quality evidence. In addition, recent oral anticoagulants that exert effect by direct inhibition of thrombin or activated factor X lack the need for monitoring and have few known drug interactions. Interest in this topic remains high. Objectives To assess the effects of extended-duration anticoagulant thromboprophylaxis for the prevention of venous thromboembolism (VTE) in people undergoing elective hip or knee replacement surgery, or hip fracture repair. Search methods The Cochrane Vascular Information Specialist searched the Specialised Register (last searched May 2015) and CENTRAL (2015, Issue 4). Clinical trials databases were searched for ongoing or unpublished studies. Selection criteria Randomised controlled trials assessing extended-duration thromboprophylaxis (five to seven weeks) using accepted prophylactic doses of LMWH, UFH, vitamin K antagonists (VKA) or direct oral anticoagulants (DOAC) compared with short-duration thromboprophylaxis (seven to 14 days) followed by placebo, no treatment or similar extended-duration thromboprophylaxis with LMWH, UFH, VKA or DOACs in participants undergoing hip or knee replacement or hip fracture repair. Data collection and analysis We independently selected trials and extracted data. Disagreements were resolved by discussion. We performed fixed-effect model meta-analyses with odds ratios (ORs) and 95% confidence intervals (CIs). We used a random-effects model when there was heterogeneity. Main results We included 16 studies (24,930 participants); six compared heparin with placebo, one compared VKA with placebo, two compared DOAC with placebo, one compared VKA with heparin, five compared DOAC with heparin and one compared anticoagulants chosen at investigators' discretion with placebo. Three trials included participants undergoing knee replacement. No studies assessed hip fracture repair. Trials were generally of good methodological quality. The main reason for unclear risk of bias was insufficient reporting. The quality of evidence according to GRADE was generally moderate, as some comparisons included a single study, low number of events or heterogeneity between studies leading to wide CIs. We showed no difference between extended-duration heparin and placebo in symptomatic VTE (OR 0.59, 95% CI 0.35 to 1.01; 2329 participants; 5 studies; high quality evidence), symptomatic deep vein thrombosis (DVT) (OR 0.73, 95% CI 0.39 to 1.38; 2019 participants; 4 studies; moderate quality evidence), symptomatic pulmonary embolism (PE) (OR 0.61, 95% CI 0.16 to 2.33; 1595 participants; 3 studies; low quality evidence) and major bleeding (OR 0.59, 95% CI 0.14 to 2.46; 2500 participants; 5 studies; moderate quality evidence). Minor bleeding was increased in the heparin group (OR 2.01, 95% CI 1.43 to 2.81; 2500 participants; 5 studies; high quality evidence). Clinically relevant non-major bleeding was not reported. We showed no difference between extended-duration VKA and placebo (one study, 360 participants) for symptomatic VTE (OR 0.10, 95% CI 0.01 to 1.94; moderate quality evidence), symptomatic DVT (OR 0.13, 95% CI 0.01 to 2.62; moderate quality evidence), symptomatic PE (OR 0.32, 95% CI 0.01 to 7.84; moderate quality evidence) and major bleeding (OR 2.89, 95% CI 0.12 to 71.31; low quality evidence). Clinically relevant non-major bleeding and minor bleeding were not reported. Extended-duration DOAC showed reduced symptomatic VTE (OR 0.20, 95% CI 0.06 to 0.68; 2419 participants; 1 study; moderate quality evidence) and symptomatic DVT (OR 0.18, 95% CI 0.04 to 0.81; 2459 participants; 2 studies; high quality evidence) compared to placebo. No differences were found for symptomatic PE (OR 0.25, 95% CI 0.03 to 2.25; 1733 participants; 1 study; low quality evidence), major bleeding (OR 1.00, 95% CI 0.06 to 16.02; 2457 participants; 1 study; low quality evidence), clinically relevant non-major bleeding (OR 1.22, 95% CI 0.76 to 1.95; 2457 participants; 1 study; moderate quality evidence) and minor bleeding (OR 1.18, 95% CI 0.74 to 1.88; 2457 participants; 1 study; moderate quality evidence). We showed no difference between extended-duration anticoagulants chosen at investigators' discretion and placebo (one study, 557 participants, low quality evidence) for symptomatic VTE (OR 0.50, 95% CI 0.09 to 2.74), symptomatic DVT (OR 0.33, 95% CI 0.03 to 3.21), symptomatic PE (OR 1.00, 95% CI 0.06 to 16.13), and major bleeding (OR 5.05, 95% CI 0.24 to 105.76). Clinically relevant non-major bleeding and minor bleeding were not reported. We showed no difference between extended-duration VKA and heparin (one study, low quality evidence) for symptomatic VTE (OR 1.64, 95% CI 0.85 to 3.16; 1279 participants), symptomatic DVT (OR 1.36, 95% CI 0.69 to 2.68; 1279 participants), symptomatic PE (OR 9.16, 95% CI 0.49 to 170.42; 1279 participants), major bleeding (OR 3.87, 95% CI 1.91 to 7.85; 1272 participants) and minor bleeding (OR 1.33, 95% CI 0.64 to 2.76; 1279 participants). Clinically relevant non-major bleeding was not reported. We showed no difference between extended-duration DOAC and heparin for symptomatic VTE (OR 0.70, 95% CI 0.28 to 1.70; 15,977 participants; 5 studies; low quality evidence), symptomatic DVT (OR 0.60, 95% CI 0.11 to 3.27; 15,977 participants; 5 studies; low quality evidence), symptomatic PE (OR 0.91, 95% CI 0.43 to 1.94; 14,731 participants; 5 studies; moderate quality evidence), major bleeding (OR 1.11, 95% CI 0.79 to 1.54; 16,199 participants; 5 studies; high quality evidence), clinically relevant non-major bleeding (OR 1.08, 95% CI 0.90 to 1.28; 15,241 participants; 4 studies; high quality evidence) and minor bleeding (OR 0.95, 95% CI 0.82 to 1.10; 11,766 participants; 4 studies; high quality evidence). Authors' conclusions Moderate quality evidence suggests extended-duration anticoagulants to prevent VTE should be considered for people undergoing hip replacement surgery, although the benefit should be weighed against the increased risk of minor bleeding. Further studies are needed to better understand the association between VTE and extended-duration oral anticoagulants in relation to knee replacement and hip fracture repair, as well as outcomes such as distal and proximal DVT, reoperation, wound infection and healing.
Download
📖 Papers frequently viewed together
20128.31Chest
1,930 Citations
149 Citations
1,046 Citations
References66
Newest
Introduction Deep vein thrombosis and pulmonary embolism are common complications post-total hip (THA) and total knee arthroplasty (TKA). Prophylaxis with direct oral anticoagulants, such as rivaroxaban extended beyond hospital discharged is commonly prescribed for the prevention of these complications. We reasoned aspirin (ASA) potentially would be an attractive alternative agent for extended prophylaxis because of its low cost, convenience and few side effects. Objective was to determine if as...
1 CitationsSource
Venous thromboembolism, including deep-vein thrombosis and pulmonary embolism, is a common, often-recurring condition that is occurring with increasing frequency, despite the availability of prophylactic treatments. The epidemiology of VTE involves interactions between predispositions to thrombosis and a range of risk factors, including hospitalization, cancer, and pregnancy.
411 CitationsSource
#1Zhong Wang (NIH: National Institutes of Health)H-Index: 12
#2Frederick A. Anderson (UMMS: University of Massachusetts Medical School)H-Index: 72
Last. Timothy Bhattacharyya (NIH: National Institutes of Health)H-Index: 26
view all 4 authors...
Background Anticoagulants reduce the risk of venous thromboembolism (VTE) after total joint replacement. However, concern remains that pharmacologic VTE prophylaxis can lead to bleeding, which may impact on postoperative complications such as infections and reoperations. Methods and Findings From the Global Orthopedic Registry (GLORY), we reviewed 3,755 patients in US who elected for primary total hip or knee arthroplasty, received either warfarin or low molecular weight heparin (LMWH) as VTE pr...
17 CitationsSource
#1Heng ZhangH-Index: 1
#2Jianhao Lin (PKU: Peking University)H-Index: 17
Last. Wei Wei (PKU: Peking University)H-Index: 2
view all 7 authors...
Abstract To compare the effects of short-term and long-term thromboprophylaxis after total hip replacement on coagulation indicators in plasma sampled before and 1, 7 and 35 days post-operation. A total of 40 patients scheduled for elective total hip replacement were randomly assigned into the short-term (n = 20) or long-term (n = 20) thromboprophylaxis groups on oral rivaroxaban 10 mg once daily for 7 or 35 days. The primary efficacy hemostatic variables included thrombin-antithrombin complexes...
2 CitationsSource
#1Aaron Liew (National University of Ireland, Galway)H-Index: 20
#2John W. Eikelboom (McMaster University)H-Index: 121
Last. Martin O'Donnell (National University of Ireland, Galway)H-Index: 79
view all 3 authors...
4 CitationsSource
#1Björn StollenwerkH-Index: 16
#2L. LeH-Index: 1
Last. Stephanie Stock (University of Cologne)H-Index: 20
view all 6 authors...
1 CitationsSource
#1N. RosencherH-Index: 1
#2J. V. LlauH-Index: 1
Last. Martin Homering (Bayer USA: Bayer Corporation)H-Index: 17
view all 6 authors...
Background Patients receiving anticoagulants could be at higher risk of compressive haematoma with neuraxial anaesthesia use. The phase III RECORD programme compared rivaroxaban with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement surgery in more than 12,500 patients. This observational analysis evaluated the risk of neuraxial haematoma after neuraxial anaesthesia in patients receiving rivaroxaban or enoxaparin using pooled RECORD1–4 data. Methods The inci...
26 CitationsSource
#1Graham F. Pineo (U of C: University of Calgary)H-Index: 28
#2Alexander Gallus (Flinders Medical Centre)H-Index: 61
Last. Lu Wang (BMS: Bristol-Myers Squibb)H-Index: 1
view all 8 authors...
Summary. Background: New oral anticoagulants for thromboprophylaxis after hip or knee arthroplasty have been given as fixed-dose regimens. Objective: To evaluate the consistency of the antithrombotic efficacy and bleeding risk of apixaban 2.5 mg twice daily compared with enoxaparin 40 mg once daily after knee or hip arthroplasty across the clinical characteristics of age, gender, body weight, body mass index (BMI) and creatinine clearance. Methods: The pooled results of the ADVANCE-2 (knee arthr...
23 CitationsSource
#1Michael R. Lassen (UCPH: University of Copenhagen)H-Index: 33
#2Michael Gent (McMaster University)H-Index: 127
Last. A.G. Turpie (McMaster University)H-Index: 7
view all 7 authors...
Post-operative complications after total hip or knee replacement can delay recovery, prolong hospitalisation, increase rates of re-admission and, in the most severe cases, lead to long-term disability or even death. In this analysis of pooled data from four large, randomised, phase III clinical trials that compared the oral, direct Factor Xa inhibitor rivaroxaban with subcutaneous enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement (n = 12 729), the incide...
35 CitationsSource
#1Bengt I. Eriksson (Sahlgrenska University Hospital)H-Index: 84
#2Nadia RosencherH-Index: 25
Last. Ola E. DahlH-Index: 40
view all 5 authors...
Abstract Introduction The RECORD programme compared oral rivaroxaban with enoxaparin for prevention of venous thromboembolism after elective total hip or knee replacement. This analysis compared the safety of concomitant use of specified medications with rivaroxaban and enoxaparin by evaluating postoperative bleeding rates from the pooled RECORD1–4 data. Materials and methods The co-medications were non-steroidal anti-inflammatory drugs and platelet function inhibitors, including acetylsalicylic...
28 CitationsSource
Cited By41
Newest
#1Christopher C. Stahl (UW: University of Wisconsin-Madison)H-Index: 7
#2Luke M. FunkH-Index: 19
Last. John E. ScarboroughH-Index: 2
view all 5 authors...
Background Hip fractures affect a vulnerable population and are associated with high rates of morbidity, mortality, and resource utilization. Although postoperative complications are a known driver of mortality and resource utilization, the comparative impacts of specific complications on outcomes is unknown. This study assessed which complications are associated with the highest effects on mortality and resource utilization for older patients who undergo hip fracture repair. Methods Patients ≥ ...
Source
#1Lily Ackermann (Thomas Jefferson University)H-Index: 2
#2Eric S. Schwenk (Thomas Jefferson University)H-Index: 13
Last. Howard H. Weitz (Thomas Jefferson University)H-Index: 26
view all 4 authors...
Morbidity and mortality rates associated with acute hip fracture remain high. Over the past decade, the management of hip fracture has shifted to emphasize prompt surgical treatment, multimodal analgesia to reduce opioid use, and incorporation of enhanced recovery pathways. Preoperative evaluation focuses on acutely correctable problems, with the understanding that delaying surgery may worsen the outcome. Prophylaxis of venous thrombo embolism, treatment of preoperative anemia and acute kidney i...
Source
#1Charlie J. Nederpelt (LUMC: Leiden University Medical Center)H-Index: 4
#1Charlie J. Nederpelt (LUMC: Leiden University Medical Center)H-Index: 1
Last. Martin G. Rosenthal (Harvard University)H-Index: 6
view all 8 authors...
Abstract Background Trauma patients are at a significant risk of venous thromboembolism (VTE), with lower extremity fractures (LEF) being independent risk factors. Use of direct oral anticoagusants (DOACs) for VTE prophylaxis is effective in elective orthopedic surgery, but currently not approved for trauma patients. The primary objective of this study was to compare the effectiveness and safety of thromboprophylaxis of DOACs with low-molecular-weight heparin (LMWH) in trauma patients sustaining...
1 CitationsSource
#1Christina Georgeades (MCW: Medical College of Wisconsin)
#1Christina Georgeades (MCW: Medical College of Wisconsin)
Last. David M. GourlayH-Index: 21
view all 3 authors...
In recent years, there has been an increased focus on developing and validating venous thromboprophylaxis guidelines in the pediatric trauma population. We review the current literature regarding the incidence of and risk factors for venous thromboembolism (VTE) and the use of prophylaxis in the pediatric trauma population. Risk factors such as age, injury severity, central venous catheters, mental status, injury type, surgery, and comorbidities can lead to a higher incidence of VTE. Risk strati...
Source
#1Banne Nemeth (LUMC: Leiden University Medical Center)H-Index: 8
#2Rob G H H Nelissen (LUMC: Leiden University Medical Center)H-Index: 67
Last. Suzanne C. Cannegieter (LUMC: Leiden University Medical Center)H-Index: 60
view all 4 authors...
Venous thromboembolism (VTE) is a common complication following total hip arthroplasty (THA) and total knee arthroplasty (TKA). Many guidelines advise on the ideal pharmacological thromboprophylaxis strategy; however, despite its use, approximately 1.5% of patients still develop symptomatic VTE. Considering the large number of THAs and TKAs performed worldwide (2.5 million in total), the impact of VTE following these interventions is enormous. This paper discusses a concept how to further lower ...
2 CitationsSource
#1Matthew A. Bartlett (Mayo Clinic)H-Index: 4
#2Karen F. Mauck (Mayo Clinic)H-Index: 16
Last. Paul R. Daniels (Mayo Clinic)H-Index: 16
view all 5 authors...
Venous thromboembolism (VTE) is a preventable cause of postoperative morbidity and mortality; however, audits suggest that the use of thromboprophylaxis is underused. In this review, we describe our approach to prevention of postoperative VTE and provide guidance on how to formulate an optimal VTE prophylaxis plan. We recommend that all patients undergo thrombosis- and bleeding-risk assessment as part of their preoperative evaluation. The risk of thrombosis can be estimated based on patient- and...
1 CitationsSource
#1Victoria L. Aime (Mayo Clinic)H-Index: 3
#2Matthew R. Neville (Mayo Clinic)H-Index: 7
Last. Robert W. Bernard (Mayo Clinic)H-Index: 5
view all 6 authors...
BACKGROUND: Deep venous thrombosis (DVT) and pulmonary embolism (PE), collectively known as venous thromboembolism (VTE), are among the most feared yet preventable surgical complications. While many recommendations exist to reduce the risk of VTE, the actual VTE prophylaxis practices of aesthetic plastic surgeons remain unknown. OBJECTIVES: The primary aim of this study was to elucidate plastic surgeons' experiences with VTE, preferred VTE prophylaxis practices and areas in which VTE prevention ...
4 CitationsSource
#1Siyuan Zhang (NUS: National University of Singapore)
view all 6 authors...
Background: Venous thromboembolism (VTE) is a serious complication that may occur after total knee arthroplasty (TKA), leading to the recommendation of routine chemoprophylaxis by international guidelines. This study aims to determine if short-duration chemoprophylaxis after TKA reduces the incidence of VTE in an Asian population. Methods: A retrospective study of 316 patients who underwent unilateral primary TKA between 1 January 2011 and 31 December 2013 was conducted. All patients received me...
Source
#1J. Gutiérrez Guisado (Universidad Francisco de Vitoria)H-Index: 2
Thromboembolism prophylaxis is well-established in major orthopaedic surgery (hip and knee arthroplasty and hip fracture surgery), with low-molecular-weight heparins the most often chosen agent. In recent years, however, direct-acting anticoagulants have been gaining ground and can be used in this scenario (except for hip fracture surgery). In the US, even aspirin could be indicated for low-risk patients who undergo hip or knee arthroplasty. For other orthopaedic procedures (leg surgery below th...
Source
#1Ioannis V. Papachristos (University of Leeds)H-Index: 1
#2Peter V. Giannoudis (University of Leeds)H-Index: 104
Thirty per cent of patients presenting with proximal femoral fractures are receiving anticoagulant treatment for various other medical reasons. This pharmacological effect may necessitate reversal prior to surgical intervention to avoid interference with anaesthesia or excessive peri/post-operative bleeding. Consequently, delay to surgery usually occurs.Platelet inhibitors (aspirin, clopidogrel) either alone or combined do not need to be discontinued to allow acute hip surgery. Platelet transfus...
Source